Neoadjuvant chemotherapy in Albinos with locally advanced skin cancer at a Blantyre Hospital: - Case Series by Chidothe, IA & Masamba, L
Malawi Medical Journal; 26(3): 97-99 September 2014 Neoadjuvant chemotherapy 97
Neoadjuvant chemotherapy in Albinos with locally 
advanced skin cancer at a Blantyre Hospital: - Case 
Series
I A. Chidothe , LMasamba  
Department of  Medicine, Oncology Unit, Queen Elizabeth Central 
Hospital
Correspondence: iachidothe@gmail.com
                         Abstract
Albinism in Africa remains a public health concern with increasing 
numbers of  advanced skin cancer in this population at presentation. 
There are challenges with availability of  Radiotherapy (RT) units in Africa 
which is an important modality for controlling loco-regional disease 
alone or in combination with surgery. Proposed chemotherapy regimens 
have not been well validated through Randomized Controlled Trials thus 
posing difficulties for standard of  care for units that do not have access to 
functional RT facilities. Malawi is one such country without radiotherapy. 
Case summary
Seven patients with locally advanced skin cancer were seen in the adult 
oncology unit at Queen Elizabeth Central Hospital in Blantyre (QECH), 
Malawi between 2010 and 2013. QECH is one of  the teaching hospitals 
in the country. All were subjected to neo-adjuvant chemotherapy. The 
primary treatment aim was cyto-reduction followed by surgery whilst the 
secondary outcome was general symptom control. Three patients achieved 
complete responses of  which two underwent resection and a pectoralis 
major myocutaneous flap. One had a near complete response and three 
showed partial responses. 
Conclusion
Neo-adjuvant chemotherapy may be a possible.
                         Introduction
Albinism is an inherited disorder characterised by a reduced 
or lack of  melanin; a photo protective chemical responsible 
for pigmentation in the body. Two major forms are described; 
Oculocutaneous (OCA) and Ocular albinism1. This makes 
albinos prone to the effects of  ultraviolet radiation2,3 such as 
skin cancer of  which squamous cell carcinoma (SCC) is the 
commonest histology4,5,6.
There is lack of  data on the standard management of  advanced 
skin cancer cases in albinos especially in limited resource 
settings. There are challenges with limited Radiotherapy (RT) 
units in developing regions like Africa generally, a modality 
which has been shown to be important for controlling 
loco-regional disease7.  Whereas the European standard for 
radiotherapy services is 250 000 people per machine, the 
International Atomic Energy Association (IAEA) through 
its programme of  action for cancer therapy (PACT) reports 
that the majority of  sub-Saharan African countries range 
from no machines to very few that serve approximately 10 
million people per machine8.
Malawi is one such country with no functional radiotherapy 
facility hence chemotherapy forms the mainstay of  treatment 
in advanced non-resectable skin cancers in albinos. The 
waiting time for a government funded external radiotherapy 
referral is a minimum of  six months. Considering this and 
advanced disease at presentation, chemotherapy in these cases 
was administered to down-stage the disease for resection 
or symptom control as surgery upfront was not possible. 
However, the proposed chemotherapy regimens have not 
been well validated through Randomized Controlled Trials 
(RCTs).
It is with this background that we present a case series to 
report feasibility of  using chemotherapy in albinos and 
demonstrating their responses to neo-adjuvant chemotherapy. 
                      Patient Summaries*
1: A 23 year old female had wide local excision and left 
superficial parotidectomy done for SCC lesions on her 
forehead and left cheek respectively. 3 months later she 
presented with a recurrence on the left cheek. She was 
started on Cisplatin and 5-Fluorouracil (PF) to which 
there was complete clinical response. Following this; she 
refused further surgery and presented 7 months later with 
another recurrence (6 × 6.5 cm) at the same site. She was 
then rechallenged with Adriamycin and Cisplatin (AP) 
with complete tumour regression. A total of  4 cycles were 
administered but she never returned for further treatment 
or follow up.
2: A 35 year old male presented with a left pre-auricular 4 × 5 
cm ulcer. He was started on PF. There was complete clinical 
response to 3 cycles of  chemotherapy which was followed 
by Pinnectomy and a Pectoralis major myocutaneous flap. 
Further pathological analysis of  the surgical specimen 
was reported as a Basal Cell Carcinoma with squamous 
differentiation. He was recommended for radiotherapy but 
never received. However, he has remained disease free for 
over 12 months.
3: A 19 year old boy presented with a 5 year history of  a 
left parietal ulcer. An excision biopsy was reported as 
invasive SCC. He was started on AP. There was a near 
complete response following 4 cycles. Subsequently there 
has been poor treatment compliance and multiple treatment 
interruptions which resulted in progressive disease. 
4: A 50 year old man presented with a left preauricular mass 
for 7 months that was associated with pain and hearing 
difficulties ipsilaterally. The lesion was 10 × 8 cm and a tru-
cut biopsy confirmed an invasive poorly differentiated SCC. 
He was started on AP. Partial response was noted after 6 
cycles.
5: A 34 year old man presented with a 3 months history of  
recurrent left cheek swelling. He had initially undergone 2 
wide local excisions at the same site and histology confirmed 
an invasive SCC. The tumour was 10 × 9 cm and he received 
3 cycles of  AP. Partial response was noted. He presented 
with progressive disease due to poor treatment compliance. 
AF was given as re-challenge but was also not completed. 
6: A 38 year old man presented with locally advanced SCC 
infiltrating into the maxillary antrum and buccal mucosal. 
There was partial response to 5 cycles of  PF but did not 
turn-up for further treatment. He presented with progressive 
disease almost a year later.
7: A 30 year old female with advanced SCC of  the right cheek; 
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she was started on Carboplatin and Adriamycin. There was 
complete response after 6 cycles followed by resection and 
a myocutaneous flap. 9 months later there was a recurrence 
on a different site (right shoulder area). She was rechallenged 
with PF but did not return to complete her treatment. This 
case was reported prior by Mapurisa and Masamba (2011) [9] 
and formed the basis for this series.
*Summary of  patient details in Table 1.
Treatment Details and Outcomes
Study population
Seven cases are here reported, two females and 5 males. The 
median age was 32 years (range 19 to 50 years) and all the 
lesions were in the head and neck region; specifically the 
cheek. The average symptom duration was 20 months.  Two 
patients presented with recurrent disease within 6 months 
following prior surgical excision (case 2.1 and 2.5). All were 
chemotherapy-naive at presentation.
Pre-Chemotherapy Work-up
Pre-chemotherapy assessment involved history taking, 
clinical examination and blood tests which included a full 
blood count, liver and renal function tests. A baseline 
chest radiograph and Liver ultrasound scan were done 
to rule out distant metastases. The desirable parameters 
for chemotherapy were a performance status as per the 
Eastern Cooperative Oncology Group (ECOG) of  ≤ 2, a 
haemoglobin count of  ≥ 8 g/dl with an absolute white cell 
count of  ≥ 2000/mm3 on full blood count, and a glomerular 
filtration rate (GFR) of  ≥ 60 ml/min based on the Cockroft-
Gault formula. 
3.3: Chemotherapy Regimen and Administration
The chemotherapy regimen included a platinum; either 
Cisplatin given at 60-70 mg/m2 on D1 if  GFR was ≥ 60ml/
min, or Carboplatin. The Carboplatin was calculated using 
Calvert’s formula at area under the time-concentration curve 
6 (AUC 6). The platinum was given with either 5-Fluorouracil 
(5FU) at 750-1000 mg/m2 D1to D4 or Adriamycin at 60 
mg/m2 D1 only cycled at 21 days. Only 1 patient received 
Adriamycin with 5FU (case 2.5). The average cycles given 
were 6.4.
Treatment Goals and Outcome
The primary treatment aim was cyto-reduction followed by 
surgery whilst the secondary outcome was general symptom 
control. Tumour response was evaluated using the RECIST 
criteria (Appendix 2). [10] Of  the three patients who showed 
complete tumour response; two underwent surgical excision, 
Pinnectomy and a Pectoralis major myocutaneous flap but 
one refused surgery. One patient showed a near complete 
response. Of  the three patients who showed partial responses 




As already demonstrated from several studies, squamous cell 
carcinoma (SCC) is the commonest histology noted in the 
African albino. Management of  skin cancers in this population 
has been compounded by several factors especially within 
Africa. For example, in this series the time to presentation 
ranged from 3 to 60 months, emphasizing extreme delay in 
presentations. As much as this was mainly due to patient 
related factors, failure of  the health system to pick up early 
stages of  the disease and delays in the referral system may 
also have contributed. This has also been reported and was 
thought to be due to poor disease understanding (mainly by 
the patients) and financial constraints2,11.  As a result many 
patients initially present with advanced disease. 
The common site for the lesions as also previously observed 
was the head and neck region. This is thought to be due 
to increased sun exposure in this area relative to other sites. 
Malawi experiences a tropical climate with more than 75% 
of  the population based in the rural area where they rely 
on subsistence farming. This means two-thirds of  the day is 
spent outdoors with increasing sun exposure. It is noteworthy 
that there were more males than females which may reflect 
gender roles especially in the rural setting and may explain in 
part the finding above. 
As part of  preventive and supportive care of  persons living 
with albinism, there is an albino clinic at our hospital that 
works together with the Albino society to manage different 
skin related conditions in this population. In addition, they 
conduct awareness campaigns annually on behavioural 
change and photo-protective measures where they distribute 
such items as sunscreen and hats. The hope therefore is that as 
these programs are sustained and built further, the incidence 
of  skin malignancies in this population should decrease in 
the near future; an approach which may also prove beneficial 
for various cancers and other non-communicable diseases.  
Of  note is that for a long time, the treatment modalities 
commonly employed for either radical or palliative intents 
in such patients have been surgery and or radiotherapy with 
variable responses4,7,11. However, there has been no concrete 
evidence shown for the role of  chemotherapy especially 
for settings without functional RT facilities. Even though 
the small total number of  patients offers some limitation in 
our series, the down-staging that occurred with neoadjuvant 
chemotherapy suggests there could be benefit in this line of  
treatment. 
Although in many of  the cases there was poor compliance 
to either treatment, follow up or both; there is evidence that 
chemotherapy seems to have been delivered safely in all 
the cases with no significant toxicities recorded. We believe 
this may partly be attributed to the symptomatic relief  
achieved once chemotherapy is initiated such that there is 
complacency in seeking further treatment evidenced by four 
patients who subsequently presented with either recurrence 
or progressive disease (case 1, 3, 5 and 6). However, other 
reasons may be financial constraints and lack of  strong 
social support. This reflects the need to extensively counsel 
our patient population on disease understanding and 
treatment implications regardless of  response to treatment 
such as regression of  lesions. In addition, it underscores 
the importance of  engaging the civil society to contribute 
towards social support for patients undergoing treatment 
with the intent of  minimizing treatment disruptions due to 
financial constraints. 
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Conclusion
This series is hypothesis generating. Neo-adjuvant 
chemotherapy seems to be a safe option in locally advanced 
skin cancer in albinos. However, to determine a true 
measure of  effect of  this approach it requires validation in 
a larger trial setting. This work also highlights the pressing 
requirement for radiotherapy and all areas relevant to cancer 
care for optimal management of  this group of  patients in 
the developing countries. 
6. Recommendation
We recommend multi-centre trials to validate the role of  neo-
adjuvant chemotherapy in albinos presenting with advanced 
skin cancer in low in-come regions like sub-Saharan Africa 
with limited access to radiotherapy services. 
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Table 1: Patient summaries, treatment and response
Case No. Age in yrs/
Sex
Site Duration of 
Symptoms 
(Months)





1 23/ F L Cheek 
(Recurrent)





2 35/ M L Ear 24 4 x 5 PF 3 Complete
3 19/ M L Ear 60 8 x 10 A 




4 50/ M L Cheek 7 10 x 8 AP 4 Partial
5 34/ M L Cheek 
(Recurrent)





6 38/ M R Cheek 4 x 3 PF 5 Partial





KEY: *RECIST criteria, P: Cisplatin or Carboplatin, F: 5-Fluorouracil, A: Adriamycin
